Furthermore, AS-IV reduces the expressions of MMP-2/9 and VAV3 in MDA-MB-231 cells by regulating the MAPK pathway, thereby downregulating tumor cell viability and growth, which is a potential strategy for treating metastatic breast cancer (Jiang et al., 2017b). The gene discussed is MMP2; the disease is neoplasm.